+

WO2007111998A3 - Compositions d'arndb et procedes de traitement d'une infection par l'hpv - Google Patents

Compositions d'arndb et procedes de traitement d'une infection par l'hpv Download PDF

Info

Publication number
WO2007111998A3
WO2007111998A3 PCT/US2007/007241 US2007007241W WO2007111998A3 WO 2007111998 A3 WO2007111998 A3 WO 2007111998A3 US 2007007241 W US2007007241 W US 2007007241W WO 2007111998 A3 WO2007111998 A3 WO 2007111998A3
Authority
WO
WIPO (PCT)
Prior art keywords
hpv
methods
dsrna
infection
hpv infection
Prior art date
Application number
PCT/US2007/007241
Other languages
English (en)
Other versions
WO2007111998A2 (fr
Inventor
John Benson
Birgit Bramlage
Kevin Fitzgerald
Pamela Tan
Hans-Peter Vornlocher
Original Assignee
Novartis Ag
Novartis Pharma Gmbh
John Benson
Birgit Bramlage
Kevin Fitzgerald
Pamela Tan
Hans-Peter Vornlocher
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag, Novartis Pharma Gmbh, John Benson, Birgit Bramlage, Kevin Fitzgerald, Pamela Tan, Hans-Peter Vornlocher filed Critical Novartis Ag
Priority to CA002644621A priority Critical patent/CA2644621A1/fr
Priority to MX2008012173A priority patent/MX2008012173A/es
Priority to JP2009502885A priority patent/JP2009531433A/ja
Priority to BRPI0709147-8A priority patent/BRPI0709147A2/pt
Priority to EP07753837A priority patent/EP1999260A2/fr
Priority to US12/294,388 priority patent/US7956177B2/en
Priority to AU2007230995A priority patent/AU2007230995B2/en
Publication of WO2007111998A2 publication Critical patent/WO2007111998A2/fr
Publication of WO2007111998A3 publication Critical patent/WO2007111998A3/fr
Priority to US13/116,947 priority patent/US20110230546A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3515—Lipophilic moiety, e.g. cholesterol
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

L'invention concerne un acide ribonucléique double brin (ARNdb) destiné au traitement d'une infection par le papillomavirus humain (HPV). L'ARNdb comprend un brin antisens ayant une séquence nucléotidique qui fait moins de 30 nucléotides de long, en général 19 à 25 nucléotides de long, et qui est sensiblement complémentaire à au moins une partie d'un gène cible d'HPV choisi parmi HPV E1, HPV E6 et le gène E6AP humain. L'invention concerne également une composition pharmaceutique comprenant l'ARNdb conjointement avec un support pharmaceutiquement acceptable ; des procédés permettant de traiter des maladies provoquées par une infection par l'HPV et l'expression du gène E6AP à l'aide de la composition pharmaceutique ; et des procédés permettant d'inhiber l'expression des gènes cibles d'HPV dans une cellule.
PCT/US2007/007241 2006-03-24 2007-03-23 Compositions d'arndb et procedes de traitement d'une infection par l'hpv WO2007111998A2 (fr)

Priority Applications (8)

Application Number Priority Date Filing Date Title
CA002644621A CA2644621A1 (fr) 2006-03-24 2007-03-23 Compositions d'arndb et procedes de traitement d'une infection par l'hpv
MX2008012173A MX2008012173A (es) 2006-03-24 2007-03-23 Composiciones de arnds y métodos para el tratamiento de infecciones por el virus de papiloma humano (hpv).
JP2009502885A JP2009531433A (ja) 2006-03-24 2007-03-23 ＨＰＶ感染処置のためのｄｓＲＮＡ組成物および方法
BRPI0709147-8A BRPI0709147A2 (pt) 2006-03-24 2007-03-23 composições de dsrna e métodos para tratamento de infecção por hpv
EP07753837A EP1999260A2 (fr) 2006-03-24 2007-03-23 Compositions d'arndb et procédés de traitement d'une infection par l'hpv
US12/294,388 US7956177B2 (en) 2006-03-24 2007-03-23 dsRNA compositions and methods for treating HPV infection
AU2007230995A AU2007230995B2 (en) 2006-03-24 2007-03-23 dsRNA compositions and methods for treating HPV infection
US13/116,947 US20110230546A1 (en) 2006-03-24 2011-05-26 dsRNA COMPOSITIONS AND METHODS FOR TREATING HPV INFECTION

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US78583706P 2006-03-24 2006-03-24
US60/785,837 2006-03-24
US82578206P 2006-09-15 2006-09-15
US60/825,782 2006-09-15

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US13/116,947 Division US20110230546A1 (en) 2006-03-24 2011-05-26 dsRNA COMPOSITIONS AND METHODS FOR TREATING HPV INFECTION

Publications (2)

Publication Number Publication Date
WO2007111998A2 WO2007111998A2 (fr) 2007-10-04
WO2007111998A3 true WO2007111998A3 (fr) 2008-05-29

Family

ID=38541679

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/007241 WO2007111998A2 (fr) 2006-03-24 2007-03-23 Compositions d'arndb et procedes de traitement d'une infection par l'hpv

Country Status (10)

Country Link
US (2) US7956177B2 (fr)
EP (1) EP1999260A2 (fr)
JP (1) JP2009531433A (fr)
KR (1) KR20080106554A (fr)
AU (1) AU2007230995B2 (fr)
BR (1) BRPI0709147A2 (fr)
CA (1) CA2644621A1 (fr)
MX (1) MX2008012173A (fr)
RU (1) RU2008141977A (fr)
WO (1) WO2007111998A2 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20090064A1 (es) * 2007-03-26 2009-03-02 Novartis Ag Acido ribonucleico de doble cadena para inhibir la expresion del gen e6ap humano y composicion farmaceutica que lo comprende
WO2010123365A1 (fr) * 2009-04-24 2010-10-28 Academisch Ziekenhuis Leiden H.O.D.N. Lumc Augmentation de l'immunogénicité de cellules épithéliales infectées par le papillomavirus humain (pvh)
AU2009222562A1 (en) * 2009-10-01 2011-04-21 Peter Maccallum Cancer Institute Cancer therapy
WO2012016139A2 (fr) 2010-07-29 2012-02-02 Sirnaomics, Inc. Compositions d'arnsi et procédés de traitement d'infections par le hpv et d'autres infections
KR101520383B1 (ko) * 2012-08-02 2015-05-15 에이비온 주식회사 Ｈｐｖ 감염과 관련된 암의 치료용 조성물
PL235847B1 (pl) * 2014-04-11 2020-11-02 Centrum Onkologii Inst Im Marii Sklodowskiej Curie Zestaw i sposób do wykrywania obecności onkogennych wirusów HPV
EP4352258A1 (fr) * 2021-06-09 2024-04-17 The Regents Of The University Of Michigan Substances et méthodes de mesure d'adntc de vph

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003008573A2 (fr) * 2001-07-17 2003-01-30 Anne Josephine Milner Extinction d'expression genique
WO2004065601A2 (fr) * 2003-01-21 2004-08-05 Alnylam Europe Ag Derives lipophiles d'acide ribonucleique a double brin

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5858987A (en) 1995-05-05 1999-01-12 Mitotix, Inc. E6AP antisense constructs and methods of use
US8202979B2 (en) 2002-02-20 2012-06-19 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid
US20070026394A1 (en) * 2000-02-11 2007-02-01 Lawrence Blatt Modulation of gene expression associated with inflammation proliferation and neurite outgrowth using nucleic acid based technologies
DE60130583T3 (de) * 2000-12-01 2018-03-22 Europäisches Laboratorium für Molekularbiologie Kleine rns moleküle, die rns-interferenz vermitteln
US20030170891A1 (en) * 2001-06-06 2003-09-11 Mcswiggen James A. RNA interference mediated inhibition of epidermal growth factor receptor gene expression using short interfering nucleic acid (siNA)
US7956176B2 (en) 2002-09-05 2011-06-07 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
ATE517992T1 (de) 2002-11-14 2011-08-15 Dharmacon Inc Funktionelle und hyperfunktionelle sirna
ATE541928T1 (de) * 2005-03-31 2012-02-15 Calando Pharmaceuticals Inc Inhibitoren der untereinheit 2 der ribonukleotidreduktase und ihre verwendungen
CN101448849B (zh) * 2006-03-31 2013-08-21 阿尔尼拉姆医药品有限公司 抑制Eg5基因表达的组合物和方法
US8598333B2 (en) * 2006-05-26 2013-12-03 Alnylam Pharmaceuticals, Inc. SiRNA silencing of genes expressed in cancer
PE20090064A1 (es) 2007-03-26 2009-03-02 Novartis Ag Acido ribonucleico de doble cadena para inhibir la expresion del gen e6ap humano y composicion farmaceutica que lo comprende

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003008573A2 (fr) * 2001-07-17 2003-01-30 Anne Josephine Milner Extinction d'expression genique
WO2004065601A2 (fr) * 2003-01-21 2004-08-05 Alnylam Europe Ag Derives lipophiles d'acide ribonucleique a double brin

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
KELLEY MELISSA L ET AL: "The global transcriptional effects of the human papillomavirus E6 protein in cervical carcinoma cell lines are mediated by the E6AP ubiquitin ligase", JOURNAL OF VIROLOGY, vol. 79, no. 6, March 2005 (2005-03-01), pages 3737 - 3747, XP002462388, ISSN: 0022-538X *
LIU XUEFENG ET AL: "The E6AP ubiquitin ligase is required for transactivation of the hTERT promoter by the human papillomavirus E6 oncoprotein", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 280, no. 11, March 2005 (2005-03-01), pages 10807 - 10816, XP002462387, ISSN: 0021-9258 *
SCHEFFNER M ET AL: "THE HPV-16 E6 AND E6-AP COMPLEX FUNCTIONS AS A UBIQUITIN-PROTEIN LIGASE IN THE UBIQUITINATION OF P53", CELL, vol. 75, no. 3, 5 November 1993 (1993-11-05), pages 495 - 505, XP002014083, ISSN: 0092-8674 *
SOUTSCHEK JUERGEN ET AL: "Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs", NATURE, vol. 432, no. 7014, 11 November 2004 (2004-11-11), pages 173 - 178, XP002333747, ISSN: 0028-0836 *

Also Published As

Publication number Publication date
KR20080106554A (ko) 2008-12-08
CA2644621A1 (fr) 2007-10-04
AU2007230995A1 (en) 2007-10-04
EP1999260A2 (fr) 2008-12-10
JP2009531433A (ja) 2009-09-03
AU2007230995B2 (en) 2011-08-11
BRPI0709147A2 (pt) 2011-06-28
US20090247607A1 (en) 2009-10-01
US20110230546A1 (en) 2011-09-22
RU2008141977A (ru) 2010-05-27
US7956177B2 (en) 2011-06-07
WO2007111998A2 (fr) 2007-10-04
MX2008012173A (es) 2008-10-03

Similar Documents

Publication Publication Date Title
WO2008116860A3 (fr) Compositions d'arn double brin et procédés de traitement d'infections par le virus du papillome humain (hpv)
WO2007056326A3 (fr) Compositions et methodes pour inhiber l'expression du gene nav1.8
WO2007115168A8 (fr) Compositions et méthodes destinées à inhiber l'expression du gène eg5
WO2007134161A8 (fr) Compositions et procédés d'inhibition de l'expression du gène pcsk9
WO2007051045A3 (fr) Compositions et methodes destinees a inhiber l'expression du gene huntingtine
WO2007127919A3 (fr) Compositions et procédés d'inhibition de l'expression d'un gène du virus jc
WO2008036933A3 (fr) Compositions et procédés servant à inhiber l'expression du gène hamp
WO2008008719A3 (fr) Compositions et procédés permettant d'inhiber l'expression du gène myc
JP7105065B2 (ja) リガンド修飾二本鎖核酸
WO2004065601A3 (fr) Derives lipophiles d'acide ribonucleique a double brin
WO2007137156A3 (fr) Modulation d'aha par l'arn et utilisateurs thérapeutiques de celle-ci
WO2005089287A3 (fr) Procedes et compositions pour l'inhibition specifique de l'expression genetique par l'arn double brin
WO2008036638A3 (fr) MODULATION PAR L'ARNi DE GÈNE SCAP ET UTILISATIONS THÉRAPEUTIQUES
WO2007128477A3 (fr) ACIDE RIBONUCLÉIQUE INTERFÉRENT COURT (siRNA) POUR ADMINISTRATION ORALE
WO2006032041A3 (fr) Compositions et procedes pour inhiber l'expression de genes anti-apoptotiques
WO2007111998A3 (fr) Compositions d'arndb et procedes de traitement d'une infection par l'hpv
IL166546A (en) Double-stranded ribonucleic acid, preparations containing it, is used in drug preparation and in vitro method to inhibit the expression of a target gene
WO2010006973A3 (fr) Compositions et procédés pour inhiber l’expression de gènes de récepteur tgf-bêta
WO2007146511A8 (fr) Composés et procédés de modulation de l'expression génique
AU2008339215A8 (en) Novel siRNA structure for minimizing off-target effects and relaxing saturation of RNAi machinery and the use thereof
CN105907756A (zh) 延长的dicer酶底物和特异性抑制基因表达的方法
WO2010013815A1 (fr) Composition destinée à inhiber l'expression d'un gène cible
NZ563845A (en) RNAi sequences against the Influenza A segment 1 PB2 gene and uses thereof as anti-viral therapeutic
WO2007137220A3 (fr) Compositions et méthodes inhibant l'expression du gène ikk-b
WO2008030996A3 (fr) Arnsi, et procédés de fabrication

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07753837

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2007753837

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2007230995

Country of ref document: AU

Ref document number: 2644621

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2007230995

Country of ref document: AU

Date of ref document: 20070323

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: MX/a/2008/012173

Country of ref document: MX

Ref document number: 1020087023178

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2009502885

Country of ref document: JP

Ref document number: 200780010541.0

Country of ref document: CN

Ref document number: 12294388

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 8957/DELNP/2008

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2008141977

Country of ref document: RU

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: PI0709147

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20080924

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载